John M. Kirkwood, MD
Professor of Medicine and Dermatology, Vice Chairman for Clinical Research, Director, Melanoma Skin and Cancer Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA
  
 
Keith T. Flaherty, MD
Assistant Professor of Medicine, Clinical Investigations Program Leader at Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
 
 
Jedd D. Wolchok, MD, PhD
Associate Director, The Ludwig Center for Cancer Immunotherapy and Assistant Attending, Melanoma-Sarcoma Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY; Assistant Professor of Medicine, Weill Medical College of Cornell University, New York, NY
  
   
 
Learning Objectives
  • Describe the scientific rational for the use of different immunotherapies in the treatment of metastatic melanoma
  • Understand the benefits and risks of chemotherapeutic agents in patients with metastatic melanoma
  • Implement strategies for minimizing treatment-related toxicities characteristic of melanoma therapy
  • Assess patients' individual risk/benefit profiles to develop individualized plans for the treatment of metastatic melanoma

This program is supported by educational grants from:
The American Academy of CME designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™